Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

被引：0
|
作者：
George Grunberger
Sarah Camp
Jeremy Johnson
Susan Huyck
Steven G. Terra
James P. Mancuso
Zhi Wei Jiang
Gregory Golm
Samuel S. Engel
Brett Lauring
机构：
[1] Grunberger Diabetes Institute,
[2] Merck & Co.,undefined
[3] Inc.,undefined
[4] Pfizer Inc.,undefined
[5] Pfizer Inc.,undefined
[6] MSD China,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Chronic kidney disease; Ertugliflozin; Glycemic control; SGLT2 inhibitor; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：49 / 66
页数：17
相关论文
共 50 条
  • [1] Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
    Grunberger, George
    Camp, Sarah
    Johnson, Jeremy
    Huyck, Susan
    Terra, Steven G.
    Mancuso, James P.
    Jiang, Zhi Wei
    Golm, Gregory
    Engel, Samuel S.
    Lauring, Brett
    [J]. DIABETES THERAPY, 2018, 9 (01) : 49 - 66
  • [2] Glycaemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from VERTIS CV
    Dagogo-Jack, S.
    Pratley, R. E.
    Cherney, D. Z. I.
    Charbonnel, B.
    McGuire, D. K.
    Cosentino, F.
    Shih, W. J.
    Liu, J.
    Frederich, R.
    Mancuso, J. P.
    Raji, A.
    Gantz, I.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 225 - 226
  • [3] Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Cherney, David Z., I
    McGuire, Darren K.
    Cosentino, Francesco
    Shih, Weichung J.
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Raji, Annaswamy
    Gantz, Ira
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [4] Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
    Hollander, Priscilla
    Liu, Jie
    Hill, Julie
    Johnson, Jeremy
    Jiang, Zhi Wei
    Golm, Gregory
    Huyck, Susan
    Terra, Steven G.
    Mancuso, James P.
    Engel, Samuel S.
    Lauring, Brett
    [J]. DIABETES THERAPY, 2018, 9 (01) : 193 - 207
  • [5] Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
    Priscilla Hollander
    Jie Liu
    Julie Hill
    Jeremy Johnson
    Zhi Wei Jiang
    Gregory Golm
    Susan Huyck
    Steven G. Terra
    James P. Mancuso
    Samuel S. Engel
    Brett Lauring
    [J]. Diabetes Therapy, 2018, 9 : 193 - 207
  • [6] Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
    Sam Miller
    Tania Krumins
    Haojin Zhou
    Susan Huyck
    Jeremy Johnson
    Gregory Golm
    Steven G. Terra
    James P. Mancuso
    Samuel S. Engel
    Brett Lauring
    [J]. Diabetes Therapy, 2018, 9 : 253 - 268
  • [7] Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
    Miller, Sam
    Krumins, Tania
    Zhou, Haojin
    Huyck, Susan
    Johnson, Jeremy
    Golm, Gregory
    Terra, Steven G.
    Mancuso, James P.
    Engel, Samuel S.
    Lauring, Brett
    [J]. DIABETES THERAPY, 2018, 9 (01) : 253 - 268
  • [8] Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Cherney, David
    Charbonnel, Bernard
    Mcguire, Darren K.
    Cosentino, Francesco
    Shih, Weichung J.
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Raji, Annaswamy
    Gantz, Ira
    [J]. DIABETES, 2021, 70
  • [9] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
    Cherney, David Z. I.
    Charbonnel, Bernard
    Cosentino, Francesco
    Dagogo-Jack, Samuel
    McGuire, Darren K.
    Pratley, Richard
    Shih, Weichung J.
    Frederich, Robert
    Maldonado, Mario
    Pong, Annpey
    Cannon, Christopher P.
    [J]. DIABETOLOGIA, 2021, 64 (06) : 1256 - 1267
  • [10] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
    David Z. I. Cherney
    Bernard Charbonnel
    Francesco Cosentino
    Samuel Dagogo-Jack
    Darren K. McGuire
    Richard Pratley
    Weichung J. Shih
    Robert Frederich
    Mario Maldonado
    Annpey Pong
    Christopher P. Cannon
    [J]. Diabetologia, 2021, 64 : 1256 - 1267
12345